Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment
Results From Phase II Trials For Lidocaine/Heparin Candidate Could Be Ready By Late 2023
Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration to develop and commercialize Alenura, a first-line drug treatment for acute pain caused by interstitial cystitis that combines lidocaine and heparin.
You may also be interested in...
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.